stonks4u
Sign up free
VALN logo

VALN Valneva SE

NASDAQ Global Select · Biotechnology · Healthcare

$7.13
+1.48 (+26.19%)

Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. A…

Market Cap: $676.09Mvalneva.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

98
98
Aug 13Aug 13

Quote

Day Range
$6.87 – $7.30
52-Week Range
$4.75 – $12.25
Volume
$2.87M
Market Cap
$676.09M
50-Day Avg
$5.25
200-Day Avg
$7.55
Prev Close
$5.65
Open
$6.99

Valuation & Ratios

P/E Ratio
-5.69
EPS
$-1.37
P/B Ratio
5.95
P/S Ratio
3.61
Debt/Equity
1.95
Current Ratio
2.38
Dividend Yield
+0.0%
Gross Margin
+38.7%

Returns & Efficiency

Return on Equity
-108.5%
Return on Assets
-28.9%
FCF Yield
-9.1%
EV/EBITDA
-14.44

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$174.66M$-115.19M$-1.32
2024$169.58M$-12.25M$-0.17
2023$153.71M$-101.43M$-1.46
2022$361.30M$-143.28M$-2.48
2021$348.08M$-73.42M$-1.50

Social Signal Score

49
5d
50
3 mentions
—
30d
49
3 mentions
—
60d
49
3 mentions
—
90d
49
3 mentions
—
news: 3

Earnings

Thu, Nov 19(in 3 months)

Consensus estimate $-0.21 per share

2of 7 quarters beat consensus

Typical surprise -103.3% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 13$-0.40 vs $-0.19miss
  • Wed, May 13$-0.42 vs $-0.21miss
  • Mon, Mar 16$-0.68 vs $-0.17miss
  • Thu, Nov 20$-0.61 vs $-0.30miss
  • Tue, Aug 12$-0.16 vs $-0.27beat
  • Wed, May 7$-0.13 vs $-0.31beat

Estimates and results for VALN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

VALNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (3)

  • Newsseekingalpha.com·1d ago·Positive

    Valneva SE (VALN) Q2 2026 Earnings Call Transcript Valneva SE (VALN) Q2 2026 Earnings Call Transcript

    View source ↗
  • Newsmarketbeat.com·2d ago·Negative

    Valneva Q2 Earnings Call Highlights Valneva NASDAQ: VALN reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer.

    View source ↗
  • Newsglobenewswire.com·2d ago·Neutral

    Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates Lyon (France), August 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half of the year ended June 30, 2026, provided key corporate updates, and reaffirmed its financial guidance for 2026. The half year financial report, including the condensed consolidated interim financial report and the half year manage…

    View source ↗